Exelixis (EXEL) Stock Analysis

November 11, 2026

This is a peer-relative look at Exelixis (EXEL): its performance, risk, profitability, growth, financial strength, dividend, and valuation are each measured against its Pharmaceuticals, Biotechnology & Life Sciences peers, so every number reads in context rather than in isolation.

Company Profile

Company profile fields for Exelixis (EXEL)
Profile Item	EXEL
Name	Exelixis Inc.
Country/Region	United States
GICS Sector	Health Care
GICS Industry Group	Pharmaceuticals, Biotechnology & Life Sciences
GICS Industry	Biotechnology
GICS Sub-Industry	Biotechnology
Market Capitalization	16.98 billion USD
Currency	USD
Exchange	Nasdaq
Listing Date	April 17, 2000
Security Type	Common Stock

Price Performance

Cumulative Growth

EXEL

GSPC

Exelixis (EXEL) vs. S&P 500 (GSPC): Growth of a $10,000 investment over the past five years. Adjusted for dividends and splits.

Trailing Returns

Loading price history…

Trailing total returns for Exelixis (EXEL) and S&P 500 (GSPC). Returns over one year are annualized.

Calendar-Year Returns

Loading price history…

Calendar-year total returns for Exelixis (EXEL) and S&P 500 (GSPC). Each bar is that year's total return, measured year-end to year-end.

Performance Metrics

Exelixis (EXEL) metric values compared with Pharmaceuticals, Biotechnology & Life Sciences industry-group medians
Metric	Current stock: EXEL	Industry group median
Total Return (1Y)	74.98%	24.62%
Total Return (3Y, Annualized)	50.33%	20.37%
Total Return (5Y, Annualized)	31.10%	-4.02%

Risk Profile

Drawdown History

EXEL

GSPC

Exelixis (EXEL) vs. S&P 500 (GSPC): Drawdown from the running peak over the past five years. Each line shows the decline from its prior peak; 0% marks a new high.

Return Distribution

Loading price history…

Distribution of monthly total returns for Exelixis (EXEL) and S&P 500 (GSPC). Each bar is the share of months whose return fell in that 5% bucket.

Risk Metrics

Exelixis (EXEL) metric values compared with Pharmaceuticals, Biotechnology & Life Sciences industry-group medians
Metric	Current stock: EXEL	Industry group median
Volatility (1Y, Annualized)	34.17%	66.36%
Beta (5Y)	0.41	0.93
Max Drawdown (5Y)	-35.41%	-80.19%

Risk-Adjusted Performance

Risk-Return Positioning

Each dot is a stock plotted by 1-year volatility (risk) and 1-year return. EXEL is highlighted; the dashed line is the Capital Allocation Line from the risk-free rate through the industry median — dots above it are stronger on a risk-adjusted basis.

Risk-Adjusted Metrics

Exelixis (EXEL) metric values compared with Pharmaceuticals, Biotechnology & Life Sciences industry-group medians
Metric	Current stock: EXEL	Industry group median
Sharpe Ratio (1Y)	2.07	0.36
Sortino Ratio (1Y)	3.23	0.58

Profitability

ROE (TTM)

Exelixis (EXEL) posts ROE of 44.32%, in the upper peer quartile. That suggests the company earns more from each dollar of shareholders’ equity than most industry peers, a useful capital-efficiency signal.

EXEL

Pharmaceuticals, Biotechnology & Life Sciences industry group

44.32%

Group distribution

Max: 109.18%
EXEL: 44.32%
Q3: 6.23%
Median: -26.66%
Q1: -64.05%
Min: -167.77%

Largest peers

LLY: 86.02%
EXEL: 44.32%
NVS: 24.33%
AZN: 22.57%
JNJ: 20.02%
MRK: 5.06%
ABBV: --

Where Exelixis (EXEL) stands on ROE within its Pharmaceuticals, Biotechnology & Life Sciences peer group — the box is the group’s distribution and the dots its largest members.

Net Margin (TTM)

Exelixis (EXEL) keeps 35.45% of revenue as net profit on net margin, above the industry benchmark range. That is unusually strong bottom-line conversion, though tax effects, asset sales, or other one-off gains should be checked before treating it as durable.

EXEL

Pharmaceuticals, Biotechnology & Life Sciences industry group

35.45%

Group distribution

EXEL: 35.45%
Max: 18.05%
Q3: 4.78%
Median: 0.00%
Q1: -4.14%
Min: -17.05%

Largest peers

EXEL: 35.45%
LLY: 31.90%
AZN: 17.68%
NVS: 17.49%
JNJ: 16.20%
ABBV: 15.67%
MRK: 3.64%

Where Exelixis (EXEL) stands on net margin within its Pharmaceuticals, Biotechnology & Life Sciences peer group — the box is the group’s distribution and the dots its largest members.

Operating Margin (TTM)

Exelixis (EXEL) turns 40.75% of revenue into operating profit, putting operating margin in the upper peer quartile. Before financing and taxes enter the picture, the day-to-day business keeps more of each sales dollar than most industry peers.

EXEL

Pharmaceuticals, Biotechnology & Life Sciences industry group

40.75%

Group distribution

Max: 83.12%
EXEL: 40.75%
Q3: 14.77%
Median: 0.00%
Q1: -78.82%
Min: -207.40%

Largest peers

LLY: 53.66%
EXEL: 40.75%
ABBV: 39.59%
MRK: 35.22%
NVS: 34.27%
AZN: 29.57%
JNJ: 25.74%

Where Exelixis (EXEL) stands on operating margin within its Pharmaceuticals, Biotechnology & Life Sciences peer group — the box is the group’s distribution and the dots its largest members.

Profitability Metrics

Exelixis (EXEL) metric values compared with Pharmaceuticals, Biotechnology & Life Sciences industry-group medians
Metric	Current stock: EXEL	Industry group median
ROE (TTM)	44.32%	-26.66%
ROA (TTM)	23.52%	-12.50%
Net Margin (TTM)	35.45%	0.00%
Operating Margin (TTM)	40.75%	0.00%
Gross Margin (TTM)	96.26%	37.87%

Growth

Revenue Growth

Exelixis (EXEL) grew revenue 6.98%, roughly around the peer group's normal range. Top-line momentum looks broadly typical for the industry.

Exelixis (EXEL): Revenue Growth across different time periods, set against Pharmaceuticals, Biotechnology & Life Sciences industry-group medians.

EPS Growth

Exelixis (EXEL) grew earnings per share 57.95%, roughly around the peer group's normal range. Bottom-line momentum looks broadly typical for the industry.

Exelixis (EXEL): EPS Growth across different time periods, set against Pharmaceuticals, Biotechnology & Life Sciences industry-group medians.

Growth Metrics

Exelixis (EXEL) metric values compared with Pharmaceuticals, Biotechnology & Life Sciences industry-group medians
Metric	Current stock: EXEL	Industry group median
Revenue Growth (YoY)	6.98%	11.45%
Revenue Growth (3Y CAGR)	12.93%	9.94%
EPS Growth (YoY)	57.95%	4.28%
EPS Growth (3Y CAGR)	70.59%	4.17%

Financial Strength

Current Ratio (MRQ)

Exelixis (EXEL) has current ratio of 3.21, in the healthier middle range for its industry. The short-term asset cushion looks balanced relative to peers rather than stretched thin.

EXEL

Pharmaceuticals, Biotechnology & Life Sciences industry group

3.21

Group distribution

Max: 25.13
Q3: 12.13
Median: 5.52
EXEL: 3.21
Q1: 2.47
Min: 0.10

Largest peers

EXEL: 3.21
LLY: 1.39
MRK: 1.35
JNJ: 1.02
AZN: 1.01
NVS: 0.88
ABBV: 0.87

Where Exelixis (EXEL) stands on current ratio within its Pharmaceuticals, Biotechnology & Life Sciences peer group — the box is the group’s distribution and the dots its largest members.

Debt / Equity (MRQ)

Exelixis (EXEL) has debt-to-equity ratio of 0.09, roughly in line with the peer group’s normal leverage range. Its mix of debt and equity looks typical for the industry.

EXEL

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.09

Group distribution

Max: 1.42
Q3: 0.65
Median: 0.15
EXEL: 0.09
Q1: 0.02
Min: 0.00

Largest peers

NVS: 1.29
LLY: 1.23
MRK: 1.20
AZN: 0.66
JNJ: 0.55
EXEL: 0.09
ABBV: --

Where Exelixis (EXEL) stands on debt-to-equity ratio within its Pharmaceuticals, Biotechnology & Life Sciences peer group — the box is the group’s distribution and the dots its largest members.

Financial Strength Metrics

Exelixis (EXEL) metric values compared with Pharmaceuticals, Biotechnology & Life Sciences industry-group medians
Metric	Current stock: EXEL	Industry group median
Current Ratio (MRQ)	3.21	5.52
Debt / Equity (MRQ)	0.09	0.15
Net Debt / EBITDA	-0.71	1.08

Dividends

Dividend Yield (TTM)

Exelixis (EXEL) pays no dividend, leaving dividend yield at 0.00% this period. Shareholders may still receive value through reinvestment or buybacks, but there is no dividend income to compare here.

EXEL

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

Group distribution

EXEL: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

Largest peers

NVS: 2.88%
ABBV: 2.40%
MRK: 2.29%
JNJ: 1.94%
AZN: 1.73%
LLY: 0.49%
EXEL: 0.00%

Where Exelixis (EXEL) stands on dividend yield within its Pharmaceuticals, Biotechnology & Life Sciences peer group — the box is the group’s distribution and the dots its largest members.

Dividend Payout Ratio (TTM)

Exelixis (EXEL) paid no earnings out as dividends this period, leaving payout ratio at 0.00%. There is no dividend payout to size against earnings.

EXEL

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

Group distribution

EXEL: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

Largest peers

MRK: 343.43%
ABBV: 117.35%
NVS: 90.46%
JNJ: 80.12%
AZN: 45.38%
LLY: 21.71%
EXEL: 0.00%

Where Exelixis (EXEL) stands on payout ratio within its Pharmaceuticals, Biotechnology & Life Sciences peer group — the box is the group’s distribution and the dots its largest members.

Dividend Metrics

Exelixis (EXEL) metric values compared with Pharmaceuticals, Biotechnology & Life Sciences industry-group medians
Metric	Current stock: EXEL	Industry group median
Dividend Yield (TTM)	0.00%	0.00%
Dividend Payout Ratio (TTM)	0.00%	0.00%

Valuation

P/E Ratio (TTM)

Exelixis (EXEL) trades at P/E ratio of 20.83, near the industry’s usual earnings multiple. The stock is not showing a clear peer discount or premium on trailing earnings.

EXEL

Pharmaceuticals, Biotechnology & Life Sciences industry group

20.83

Group distribution

Max: 85.34
Q3: 43.46
Median: 26.69
EXEL: 20.83
Q1: 13.30
Min: 0.07

Largest peers

MRK: 148.21
ABBV: 50.05
LLY: 43.95
JNJ: 41.92
NVS: 31.02
AZN: 26.37
EXEL: 20.83

Where Exelixis (EXEL) stands on P/E ratio within its Pharmaceuticals, Biotechnology & Life Sciences peer group — the box is the group’s distribution and the dots its largest members.

P/S Ratio (TTM)

Exelixis (EXEL) trades at 6.80 on P/S ratio, roughly in the peer group’s normal range. The market is not making a strong cheap-or-rich statement about its revenue base.

EXEL

Pharmaceuticals, Biotechnology & Life Sciences industry group

6.80

Group distribution

Max: 58.18
Q3: 25.77
Median: 7.30
EXEL: 6.80
Q1: 3.01
Min: 0.01

Largest peers

LLY: 13.95
ABBV: 7.80
EXEL: 6.80
JNJ: 6.69
MRK: 5.37
NVS: 5.35
AZN: 4.63

Where Exelixis (EXEL) stands on P/S ratio within its Pharmaceuticals, Biotechnology & Life Sciences peer group — the box is the group’s distribution and the dots its largest members.

P/B Ratio (MRQ)

Exelixis (EXEL) trades at 9.28 on P/B ratio, in the higher book-value quartile. The market is paying a premium to book, so stronger ROE, cleaner assets, or a better growth profile need to justify it.

EXEL

Pharmaceuticals, Biotechnology & Life Sciences industry group

9.28

Group distribution

Max: 13.53
EXEL: 9.28
Q3: 6.54
Median: 3.25
Q1: 1.69
Min: -5.59

Largest peers

LLY: 29.96
EXEL: 9.28
NVS: 8.25
JNJ: 8.16
MRK: 8.06
AZN: 5.59
ABBV: -112.34

Where Exelixis (EXEL) stands on P/B ratio within its Pharmaceuticals, Biotechnology & Life Sciences peer group — the box is the group’s distribution and the dots its largest members.

Valuation Metrics

Exelixis (EXEL) metric values compared with Pharmaceuticals, Biotechnology & Life Sciences industry-group medians
Metric	Current stock: EXEL	Industry group median
P/E Ratio (TTM)	20.83	26.69
P/S Ratio (TTM)	6.80	7.30
P/B Ratio (MRQ)	9.28	3.25
Free Cash Flow Yield (TTM)	4.47%	-1.66%